Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension

References

• Appenzeller P, Lichtblau M, Berlier C, et al. Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. Pulm Circ. 2022;12(1):e12001. doi: 10.1002/pul2.12001
   PubMedGoogle Scholar
• Hansmann G. Pulmonary hypertension in infants, children, and young adults. J Am Coll Cardiol. 2017;69(20):2551–2569. doi: 10.1016/j.jacc.2017.03.575
   PubMed Web of Science ®Google Scholar
• Kwiatkowska J, Zuk M, Migdal A, et al. Children and adolescents with pulmonary arterial hypertension: Baseline and follow-up data from the polish registry of pulmonary hypertension (BNP-PL). J Clin Med. 2020;9(6):1717. doi: 10.3390/jcm9061717
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012;125(1):113–122. doi: 10.1161/CIRCULATIONAHA.111.026591
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349. doi: 10.7326/0003-4819-115-5-343
   PubMed Web of Science ®Google Scholar
• Guillevin L, Armstrong I, Aldrighetti R, et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev. 2013;22(130):535–542. doi: 10.1183/09059180.00005713
   PubMedGoogle Scholar
• Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019;38(9):879–901. doi: 10.1016/j.healun.2019.06.022
   PubMed Web of Science ®Google Scholar
• Issapour A, Frank B, Crook S, et al. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. Pediatr Pulmonol. 2022;57(3):724–733. doi: 10.1002/ppul.25796
   PubMed Web of Science ®Google Scholar
• You R, Qian X, Tang W, et al. Cost effectiveness of Bosentan for pulmonary arterial hypertension: A systematic review. Can Respir J. 2018;2018:1–12. doi: 10.1155/2018/1015239
   Web of Science ®Google Scholar
• Zhao Q, Guo N, Chen J, et al. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis. J Clin Pharm Ther. 2022;47(2):146–156. doi: 10.1111/jcpt.13481
   PubMed Web of Science ®Google Scholar
• Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2013;48(1):27–34. doi: 10.1002/ppul.22555
   PubMed Web of Science ®Google Scholar
• Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs. 2014;16(1):43–65. doi: 10.1007/s40272-013-0052-2
   PubMed Web of Science ®Google Scholar
• (DANE) DNdE. Archivo nacional de datos 2019 [ Available from: https://sitios.dane.gov.co/anda-index/.
   Google Scholar
• Social MdSyP. Cifras de aseguramiento en salud 2023 [ Available from: https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx.
   Google Scholar
• Social MdSyP. Resolucion 2808 2022 [ Available from: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%202808%20de%202022.pdf.
   Google Scholar
• Buendia JA, Lindarte EF, Guerrero Patino D. Phosphodiesterase 5 inhibitor for pediatric pulmonary arterial hypertension: A cost-utility analysis. Value Health Reg Issues. 2023;36:44–50. doi: 10.1016/j.vhri.2023.02.001
   PubMedGoogle Scholar
• Buendia JA, Patino DG, Lindarte EF. Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis. Pediatr Pulmonol. 2023;58(5):1562–1568. doi: 10.1002/ppul.26361
   PubMed Web of Science ®Google Scholar
• Chen T, Chen J, Chen C, et al. Systematic review and cost-effectiveness of bosentan and sildenafil as therapeutic drugs for pediatric pulmonary arterial hypertension. Pediatr Pulmonol. 2021;56(7):2250–2258. doi: 10.1002/ppul.25427
   PubMed Web of Science ®Google Scholar
• Barbera JA, Escribano P, Morales P, et al. Standards of care in pulmonary hypertension. Rev Esp Cardiol. 2008;61(2):170–184. doi: 10.1016/S1885-5857(08)60093-6
   Web of Science ®Google Scholar
• Berger RM, Haworth SG, Bonnet D, et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtension. Int J Cardiol. 2016;202:52–58. doi: 10.1016/j.ijcard.2015.08.080
   PubMed Web of Science ®Google Scholar
• Ivy D, Beghetti M, Juaneda-Simian E, et al. A randomized study of safety and efficacy of two doses of Ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. The Journal Of Pediatrics: X. 2020;5:100055. doi: 10.1016/j.ympdx.2020.100055
   PubMedGoogle Scholar
• Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant. 2007;26(2):181–187. doi: 10.1016/j.healun.2006.11.009
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–3019. doi: 10.1161/CIRCULATIONAHA.107.742510
   PubMed Web of Science ®Google Scholar
• Liu HL, Chen XY, Li JR, et al. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: A meta-analysis of randomized controlled trials. Chest. 2016;150(2):353–366. doi: 10.1016/j.chest.2016.03.031
   PubMed Web of Science ®Google Scholar
• Coyle K, Coyle D, Blouin J, et al. Cost effectiveness of first-line oral therapies for pulmonary arterial hypertension: A modelling study. Pharmacoeconomics. 2016;34(5):509–520. doi: 10.1007/s40273-015-0366-8
   PubMed Web of Science ®Google Scholar
• Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914–1923. doi: 10.1161/CIRCULATIONAHA.113.005698
   PubMed Web of Science ®Google Scholar
• Monographs DA 2023 [ Available from: https://www.drugs.com/monograph/ambrisentan.html.
   Google Scholar
• Londoño DVC, Dueñas R, Gómez E, et al. Determinación de los costos directos e indirectos en hipertensión pulmonar en Colombia. Rev Colomb Neumol. 2013;25(3):145–156. doi: 10.30789/rcneumologia.v25.n3.2013.548
   Google Scholar
• Caicedo-Cuenca LM. Enfoque de la hipertensión pulmonar en el paciente pediátrico. Revista Colombiana de Cardiología. 2017;24:89–97. doi: 10.1016/j.rccar.2017.08.011
   Google Scholar
• Erika BR, Steven HA, Ian A, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916. doi: 10.1183/13993003.01916-2018
   PubMed Web of Science ®Google Scholar
• Espinosa O, Rodriguez-Lesmes P, Orozco L, et al. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2022;37(3):359–368. doi: 10.1093/heapol/czab146
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1–5. doi: 10.1016/j.jval.2013.02.010
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud C. Sistema de Informacion de Precios de Medicamentos ( SISMED) 2021 [03/07/2121]. Available from: www.sispro.gov.co/central-prestadores-de-servicios/Pages/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx.
   Google Scholar
• Consortium YHE Net monetary benefit [ online] 2016 [ Available from: https://yhec.co.uk/glossary/net-monetary-benefit/.
   Google Scholar
• Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99(9):1197–1208. doi: 10.1161/01.CIR.99.9.1197
   PubMed Web of Science ®Google Scholar
• Gorenflo M, Ziesenitz VC. Treatment of pulmonary arterial hypertension in children. Cardiovasc Diagn Ther. 2021;11(4):1144–1159. doi: 10.21037/cdt-20-912
   PubMed Web of Science ®Google Scholar